Although the results were achieved using a different method of p53 reactivation and different experimental approaches, the discrepancy of the results of the two different models of autoimmune diseases may indicate that p53 activation cannot be used as an immunotherapeutic approach for all categories of autoimmune disorders. The gene discussed is TP53; the disease is autoimmune disease.